Ocumension Therapeutics (HKSE:01477) Debt-to-Revenue

: 0.12 (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

Debt-to-Revenue measures a company's ability to pay off its debt.

Ocumension Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was HK$14.4 Mil. Ocumension Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was HK$12.4 Mil. Ocumension Therapeutics's annualized Revenue for the quarter that ended in Jun. 2023 was HK$226.8 Mil. Ocumension Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 was 0.12.

Ocumension Therapeutics Debt-to-Revenue Historical Data

The historical data trend for Ocumension Therapeutics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

6.64

0.55

0.20

0.19

0.56

Ocumension Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue							0.16	0.37	0.14	0.12	0.48

Competitive Comparison

For the Biotechnology subindustry, Ocumension Therapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocumension Therapeutics Debt-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Ocumension Therapeutics's Debt-to-Revenue falls into.

Ocumension Therapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Ocumension Therapeutics's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(13.719	+	19.31)	/	177.51
	=	0.19

Ocumension Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(14.356	+	12.393)	/	226.842
	=	0.12

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2023) Revenue data.

Ocumension Therapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocumension Therapeutics (HKSE:01477) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN

Website

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Ocumension Therapeutics (HKSE:01477) Headlines

No Headlines